Individualized Chemotherapy
Phase 2Small molecule
Individualized Chemotherapy is one of 103 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.
3
Indications
5
Total Trials
4
Active Trials
102
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Individualized Chemotherapy
ZZhejiang University
Phase 2
Byetta
AstraZenecaPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.Preclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma2 trials
Pancreatic Cancer2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Individualized Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZhejiang University